- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04399798
Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial (BREATH)
A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia
The objective of the study is to assess the efficacy and safety of Baricitinib in the treatment of patients with COVID-19 pneumonia.
This will be a proof-of-concept trial with an exploratory single-arm proof of concept Phase IIa study to assess the efficacy and safety profile of Baricitinib in a limited number of patients with severe acute respiratory syndrome (SARS)-CoV-2 pneumonia. If the initial proof of concept phase will lead to favourable results, an open-label, Phase II, randomized controlled trial will be then designed and performed to confirm the results obtained in the proof of concept phase. The proof-of-concept phase guarantees that no safety issues arise on a limited number of patients in the use of a drug new to the current condition being treated.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sara Monti, MD
- Phone Number: 0382501878
- Email: sara.saramonti@gmail.com
Study Contact Backup
- Name: Valentina Zuccaro, MD
- Phone Number: 0382501080
- Email: V.Zuccaro@smatteo.pv.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to obtain informed patient consent noting the limitations of existing knowledge regarding Baricitinib's efficacy and the labeled warning and precautions as the proposed use is outside the approved indication, as well as the presence of known risk of being treated with Baricitinib while the subject of an active infection
- informed Consent as documented by signature
- patients with a confirmed SARS-CoV-2 pneumonia
- adult patients aged 18-74 years old
- infiltrates at chest radiography
- c-reactive protein level greater than 10 mg/dl or ferritin level > 900 ug/L
- Lymphocyte count less than 1500/mmc
- > 200 PaO2/FiO2 ≤ 300
Exclusion Criteria:
- patients aged < 18 years old and ≥ 75 years old
- concomitant bacterial infection
- lymphopenia less than 500/mmc
- hemoglobin < 8 g/dl
- absolute neutrophil count < 1 x 109 cells/L
- requiring continuous positive airway pressure (C-PAP) or mechanical ventilation
- sudden clinical deterioration requiring intensive care unit access
- known hypersensitivity or allergy to the study drug
- Creatinine clearance < 30 mL/min; if the creatinine clearance is between 30 and 60 mL/min the dose of Baricitinib should be reduced to 2 mg/daily
- Severe hepatic impairment (no dose adjustment of Baricitinib is required in mild or moderate hepatic impairment)
- Pregnant or breast-feeding
- Active tuberculosis
- Evidence of active hepatitis B (HBV) (HbsAg positive) or with detectable hepatitis C virus (HCV)-RNA, human immunodeficiency virus (HIV)
- Ongoing, acute diagnosis of deep venous thrombosis/pulmonary embolism (DVT/PE)
- Previous diagnosis of DVT/PE
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Baricitinib active treatment
Baricitinib 4 mg/day
|
4 mg/day for 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to treatment: absence of moderate to severe oxygenation impairment (Berlin criteria)
Time Frame: 8 days
|
A patient is consider responder in the absence of either moderate to severe oxygenation impairment according to Berlin criteria - measured as Partial pressure of oxygen/fraction inspired oxygen (PaO2/FiO2)
|
8 days
|
Response to treatment: survival
Time Frame: 8 days
|
Absence of death within 8 days from enrollment
|
8 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To quantify the rate of each of: moderate or severe oxygenation impairment within 8 days
Time Frame: 8 days
|
Moderate to severe oxygenation impairment according to Berlin criteria (measured as PaO2/FiO2)
|
8 days
|
To quantify the rate of each of: moderate or severe oxygenation impairment within 15 days
Time Frame: 15 days
|
Moderate to severe oxygenation impairment according to Berlin criteria (measured as PaO2/FiO2)
|
15 days
|
Mortality
Time Frame: 8 days and 15 days
|
To quantify mortality within 8 and 15 days
|
8 days and 15 days
|
Peripheral capillary oxygen saturation (SpO2)
Time Frame: 8 days; 15 days
|
SpO2 will be assessed with the median and 25th-75th percentiles
|
8 days; 15 days
|
Partial pressure of oxygen/fraction inspired oxygen (PaO2/FiO2)
Time Frame: 8 days; 15 days
|
PaO2/FiO2 will be assessed with the median and 25th-75th percentiles
|
8 days; 15 days
|
To assess the rate of patients admitted to the intensive care unit
Time Frame: 8 days; 15 days
|
Number of patients over the number of patients enrolled
|
8 days; 15 days
|
To measure the length of hospital stay
Time Frame: 8 days; 15 days
|
Median number of days and 25th-75th percentiles
|
8 days; 15 days
|
28-day mortality
Time Frame: 28 days
|
To quantify 28-day mortality
|
28 days
|
To quantify the rate of re-admission within 28 days
Time Frame: 28 days
|
Number of patients readmitted over the number patients enrolled
|
28 days
|
To quantify the cumulative incidence and severity of adverse events
Time Frame: 28 days
|
Number, type, and severity of adverse events
|
28 days
|
Interleukin (IL)-1; IL-2; IL-10; IL-6; IL-8; IL-17; IL-2 receptor levels;
Time Frame: 15 days
|
Serial serum assessments from baseline up to 15 days
|
15 days
|
TNFalpha; vascular endothelial growth factor (VEGF); interferon gamma (IFNgamma) levels
Time Frame: 15 days
|
Serial serum assessments from baseline up to 15 days
|
15 days
|
Viral load analyses
Time Frame: 15 days
|
Serial assessments from baseline up to 15 days for viral load persistence
|
15 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carlomaurizio Montecucco, Prof, Rheumatology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy
- Study Chair: Raffaele Bruno, Prof, Infectious Diseases; IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy
Publications and helpful links
General Publications
- Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4. No abstract available. Erratum In: Lancet. 2020 Jun 20;395(10241):1906.
- Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. No abstract available.
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-001185-11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corona Virus Infection
-
Ain Shams UniversityMisr International UniversityCompletedCorona Virus Infection | Corona Virus Disease 19 (Covid19) | Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)Egypt
-
Montreal Heart InstituteNational Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation and other collaboratorsTerminatedCorona Virus InfectionSpain, United States, Canada, Brazil, Greece, South Africa
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Investigación Biomédica de SalamancaTerminated
-
ANRS, Emerging Infectious DiseasesSciences Economiques et Sociales de la Santé & Traitement de l'Information... and other collaboratorsWithdrawn
-
National Institute of Allergy and Infectious Diseases...CompletedCorona Virus InfectionUnited States
-
The Cleveland ClinicCompletedCOVID | Corona Virus InfectionUnited States
-
NeurognosUnknownCOVID | Corona Virus Infection | SARS-CoV2Chile
-
Chronic Obstructive Pulmonary Disease Trial Network...TerminatedVirus Diseases | Corona Virus Infection | Infection ViralDenmark
-
University of Sao PauloMaria Aparecida de Andrade Moreira Machado; Thais Marchini de Oliveira ValarelliNot yet recruitingCorona Virus Infection | Exposure During Pregnancy
-
National Research Center for Cardiac Surgery, KazakhstanNazarbayev University Medical CenterRecruitingCovid19 | Corona Virus InfectionKazakhstan
Clinical Trials on Baricitinib
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Aaron R. MangoldCompletedCutaneous Lichen PlanusUnited States
-
Tianjin Medical University General HospitalRecruitingNMO Spectrum DisorderChina
-
Peking University People's HospitalRecruitingImmune Thrombocytopenia | ITPChina
-
Eli Lilly and CompanyCompletedHealthy VolunteersUnited Kingdom
-
University of ManchesterKarolinska Institutet; Eli Lilly and Company; Clinical Trials Unit, ManchesterCompletedIdiopathic Inflammatory MyopathiesUnited Kingdom
-
University of WashingtonWithdrawn
-
Eli Lilly and CompanyRecruitingCovid19 | Corona Virus InfectionUnited States, Spain, Mexico, Belgium, Brazil
-
Eli Lilly and CompanyRecruitingJuvenile Idiopathic ArthritisBelgium, Spain, Australia, India, Japan, Italy, Czechia, Germany, Austria, France, United Kingdom, China, Mexico, Israel, Brazil, Denmark, Poland, Russian Federation, Argentina, Turkey